A group of 12 international biotechnology associations has written to the US Patent and Trademark Office (USPTO), raising concerns about the office’s guidelines on determining the patent eligibility of natural products in the aftermath of the Myriad and Mayo cases.
Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world.
Personal health records company MMR Global has entered into a licensing agreement with Australian medical database company Claydata.
Stem cell research companies in Canada and Australia have teamed up to support increased research and development in both countries.
Gilead Sciences has received another challenge to its application to patent its new hepatitis C drug Sovaldi (sofosbuvir) in India.
South Korean cancer vaccine maker KAEL-GemVax has appointed CPA Global as its IP management specialist.
Australia’s antitrust regulator has launched proceedings against Pfizer’s Australian arm, accusing it of abusing its power when supplying cholesterol-lowering drug atorvastatin to pharmacies.
The High Court in Australia has said for the first time that a method of medical treatment for the human body can be a patentable invention.
Takeda has announced that Christophe Weber, a member of GlaxoSmithKline’s global corporate executive team, will be joining the company as chief operating officer by April next year.
The US government has said it is now advocating a “differential” approach to policies on patenting drugs as part of continuing trade negotiations with Pacific countries.